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A	nosocomial	cluster	induced	by	co-infections	with	avian	in-
fluenza	A(H7N9)	 and	A(H1N1)pdm09	 (pH1N1)	 viruses	 oc-
curred	in	2	patients	at	a	hospital	in	Zhejiang	Province,	China,	
in	January	2014.	The	index	case-patient	was	a	57-year-old	
man	with	chronic	lymphocytic	leukemia	who	had	been	occu-
pationally	exposed	to	poultry.	He	had	co-infection	with	H7N9	
and	 pH1N1	 viruses.	A	 71-year-old	man	 with	 polycythemia	
vera	who	was	in	the	same	ward	as	the	index	case-patient	for	
6	days	acquired	infection	with	H7N9	and	pH1N1	viruses.	The	
incubation	period	for	the	second	case-patient	was	estimated	
to	be	<4	days.	Both	case-patients	died	of	multiple	organ	fail-
ure.	Virus	genetic	sequences	from	the	2	case-patients	were	
identical.	Of	103	close	contacts,	none	had	acute	respiratory	
symptoms;	all	were	negative	for	H7N9	virus.	Serum	samples	
from	both	case-patients	demonstrated	strong	proinflamma-
tory	 cytokine	 secretion	but	 incompetent	 protective	 immune	
responses.	These	findings	strongly	suggest	limited	nosoco-
mial	co-transmission	of	H7N9	and	pH1N1	viruses	from	1	im-
munocompromised	patient	to	another.
As of January 4, 2016, a novel avian influenza A vi-rus, A(H7N9), first identified in China in March 
2013 (1), had caused 676 laboratory-confirmed cases of 
influenza in humans and 275 influenza-associated deaths 
in mainland China (Chinese Center for Disease Control 
and Prevention, unpub. data). Most H7N9 virus infections 
have been acquired through exposure to live poultry mar-
kets (LPMs) in urban settings (2) and have been sporadic, 
but a few have occurred in clusters of >2 epidemiologi-
cally linked cases (3). Human-to-human transmission is 
difficult to prove because exposure to a common source 
often cannot be excluded. Nosocomial transmission of 
H7N9 virus has recently been reported in China’s Zhe-
jiang Province (4). We investigated possible nosocomial 
co-transmission of H7N9 and influenza A(H1N1)pdm09 
(pH1N1) viruses between 2 immunocompromised pa-
tients in Zhejiang Province.
Methods
Patients and Samples Collection
China’s national surveillance system for influenza-like ill-
ness (ILI), severe acute respiratory illness, and pneumonia 
of unexplained origin indicated a cluster of 2 H7N9 virus 
infections occurring in the same ward at Taizhou Hospital 
in Zhejiang Province, China, during January 10–15, 2014. 
We collected throat swabs and serum from the 2 affected 
case-patients for virologic, serologic, and cytokine studies. 
We collected specimens from the upper respiratory tract by 
using pharyngeal swabs or from the lower tract by using 
bronchoalveolar lavage. These specimens were collected 
on January 19 and 21 from the index case-patient and the 
second case-patient, respectively.
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Nosocomial	Cluster	with	A(H7N9)	and	A(H1N1)pdm09
Controls
We retrieved stored serum samples from 21 other H7N9 
virus–infected patients (mean age 60 years, range 
44–76 years) from Zhejiang Province (mean number 
of days from onset 6 days, range 2–10 days). Serum 
samples from 6 healthy volunteers were collected for use 
as controls.
Investigation of Contacts
Close contacts were defined as described (1); all health-
care workers, patients sharing the same ward, and those 
patients’ family members were included. Close contacts 
were placed under daily active surveillance for 7 days. 
After written informed consent was obtained, a structured 
questionnaire was used to gather information on demo-
graphic characteristics, exposure history, and clinical out-
come. Throat swab samples for H7N9 virus testing were 
taken from all close contacts during the observation peri-
od, and convalescent-phase serum samples were collected 
3–4 weeks after the last exposure to a patient with H7N9 
virus infection.
Laboratory Methods
Specific real-time reverse transcription PCR (rRT-PCR) 
assays for seasonal influenza viruses (H1, H3, and B) and 
avian influenza viruses (H5N1 and H7N9) were conducted 
as described (5). All specimens found to be positive for 
virus RNA were inoculated into MDCK cell cultures for 
virus isolation (2). Virus genetic sequences were obtained 
directly from clinical specimens or from virus isolates by 
using an MiSeq desktop sequencer (Illumina, Inc., San Di-
ego, CA, USA) as described (6–8). We designed 3 differ-
ent controls to verify results: the H7N9 RNA negative and 
positive controls and an MDCK cell control.
Microneutralization (MN) and hemagglutina-
tion inhibition (HI) assays were performed by using A/
Anhui/1/2013(H7N9) virus antigen in accordance with 
World Health Organization protocols (9). A titer of >1:40 
was defined as seropositive.
Concentrations of cytokines and chemokines in se-
rum were measured by using the Bio-PlexPro Human 
Cytokine Array 27-Plex Group I and 21-Plex Group 
II (Bio-Rad, Hercules, CA, USA). Raw data were 
analyzed by using xPONENT (Merck Millipore, Darm-
stadt, Germany).
Statistical Analyses
A value of 0.1 pg/mL for cytokine level was assumed for 
statistical purposes in cases in which the concentration 
was undetectable. The 95% CIs for the cytokine levels of 
healthy controls and the control patients with H7N9 virus 
infection were generated by using SPSS software version 
17.0 (SPSS Inc., Chicago, IL, USA).
Ethics
This research was determined by the China’s National 
Health and Family Planning Commission to be part of a 
continuing public health outbreak investigation and there-
fore exempt from institutional review board assessment. 
The protocol for collection of epidemiologic data and 
serologic testing of close contacts was approved by the 
institutional review board of the Zhejiang Provincial Cen-
ter for Disease Control and Prevention. Written informed 
consent was obtained from all contacts and controls who 
participated.
Results
Clinical Features of the 2 Confirmed Cases
The index case-patient was a 57-year-old man with un-
treated, Rai stage IIIA chronic lymphocytic leukemia, 
which manifested itself as absolute lymphocytosis, anemia, 
and cervical lymphadenopathy but was otherwise asymp-
tomatic. On January 8, 2014, the patient experienced on-
set of fever, chills, and mild cough with sputum (Figure 
1). He had not received a seasonal influenza vaccination. 
Two days later, he was admitted to the hematology ward 
at Taizhou Hospital (bed 26) because of continued fever 
(Figure 2; online Technical Appendix Figures 1 and 2, 
http://wwwnc.cdc.gov/EID/article/22/4/15-1561-Techapp.
pdf). Chest radiography performed 4 days after disease 
onset indicated consolidation of the left lower lung (on-
line Technical Appendix Figure 3). On day 7 of illness, 
the patient experienced rapid respiratory deterioration that 
required mechanical ventilation. He was transferred to the 
intensive care unit (ICU) of the respiratory ward (bed 3) 
(online Technical Appendix Figure 4). Oral oseltamivir (75 
mg twice a day) was started on day 10 of illness. A throat 
swab sample collected on day 11 of illness was positive for 
H7N9 and pH1N1 viruses. The patient was then moved to 
the department of infectious diseases (bed 10) for isolation 
(online Technical Appendix Figure 5). On day 10 of illness, 
the geometric mean titer of the H7-specific antibody from 
MN was 63.5. On day 15 of illness, the patient died of com-
plications, including acute respiratory distress syndrome, 
septic shock, and multiorgan failure (Figure 1; Table 1).
The second case-patient was a 71-year-old man with 
diabetes who had been undergoing insulin therapy for 20 
years. He had received no vaccination against seasonal in-
fluenza. He had polycythemia vera that had been diagnosed 
5 years before and was undergoing cytoreductive therapy 
with interferon and hydroxyurea. On December 30, 2013, 
he was admitted to a hospital in Jiaojiang District (also lo-
cated in Taizhou) for mild fever (37.8°C) that was compat-
ible with adverse effects from interferon therapy (Figure 
1). The fever resolved by January 5, 2014. On January 8, 
the patient was transferred to the hematology ward (bed 27, 
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next to the index case-patient) in Taizhou Hospital to opti-
mize clinical management of his polycythemia vera (Figure 
2). He remained afebrile until January 14, when he experi-
enced a high fever (39.7°C) and productive cough. One day 
later, the patient received inhalation and parenteral meth-
ylprednisolone therapy for asthma. On January 19, short-
ness of breath developed, and he was moved to the hospital 
ICU, where tracheal intubation and mechanical ventilation 
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Figure 1.	Timeline	of	pertinent	exposures,	dates	of	illness	onset,	and	virologic	findings	for	2	patients	(index	case-patient	and	case-
patient	2)	who	were	co-infected	with	avian	influenza	A(H7N9)	and	A(H1N1)pdm09,	and	3	non–H7N9-infected	patients	who	shared	
the	same	hematology	ward,	Taizhou	Hospital	(hospital	A),	Zhejiang	Province,	China,	January	10–15,	2014.	Orange	box	indicates	the	
period	when	patients	2–5	were	exposed	to	the	index	case-patient.	Blue	line	indicates	that	the	period	when	the	3	non–H7N9-infected	
patients	(3–5)	were	exposed	to	case-patient	2.	Index	case-patient	was	a	57-year-old	man	with	confirmed	co-infection	with	H7N9	and	
pH1N1	viruses.	Case-patient	2	was	a	71-year-old-man	also	with	confirmed	co-infection	with	H7N9	and	pH1N1	viruses.	Patient	3	was	a	
78-year-old	man	with	chronic	B	lymphoma	cell	leukemia.	Patient	4	was	a	50-year-old	man	with	acute	myeloid	leukemia.	Patient	5	was	
a	61-year-old	man	with	macroglobulinemia.	H7N9,	avian	influenza	A(H7N9)	virus;	HI,	hemagglutination	inhibition;	ICU,	intensive	care	
unit;	LPM,	live	bird	market;	NPPV,	noninvasive	positive	pressure	ventilation;	pH1N1,	influenza	A(H1N1)pdm09	virus;	rRT-PCR,	real-time	
reverse	transcription	PCR.	
Nosocomial	Cluster	with	A(H7N9)	and	A(H1N1)pdm09
were initiated (online Technical Appendix Figure 6). The 
next day, oseltamivir treatment (75 mg 2×/d) was initiated, 
and throat swab samples collected for virology testing were 
positive for influenza H7N9 and pH1N1 viruses. The pa-
tient was transferred to the Infectious Disease Department 
on January 21 (online Technical Appendix Figure 7). The 
geometric mean titers obtained through H7N9 virus MN 
on day 9 of illness was 113.1. The patient died on day 10 
of acute respiratory distress syndrome and multiple organ 
failure (Figure 1; Table 1).
Epidemiologic Links and Exposure History
The index case-patient lived with 4 family members in a 
3-floor house in Linhai District. The second case-patient 
lived with 2 family members in an apartment in Jiaoji-
ang District and had not come into contact with the index 
case-patient before being hospitalized. No pets, domestic 
animals, or birds were present in the immediate vicin-
ity of the residences of either patient. However, the index 
case-patient worked daily as a butcher in an LPM near his 
residence during the 2 weeks before illness onset; the last 
known exposure in the LMP occurred on January 7 (online 
Technical Appendix Figures 8, 9). The second case-patient 
had no history of exposure to live birds or LPMs in the 2 
weeks before his hospital admission. The 2 patients had no 
history of eating poultry or known contact with a person 
with febrile illness in the 2 weeks before onset.
The second case-patient (in bed 27) shared the same 
room and was in the adjacent bed to the index case-pa-
tient (in bed 26) during January 10–15 (Figure 2). Dur-
ing this period, the index case-patient remained mostly 
confined to his bed, whereas the second patient was am-
bulatory. Aerosol-generating procedures were performed 
for the index case-patient on January 14–15, including 
continuous oxygen mask inhalation and negative pres-
sure suction. Endotracheal intubation and bag valve mask 
ventilation was used for 2 hours and mechanical ventila-
tion for 5 hours until he was transferred to the ICU on 
January 15. During January 10–15, the index case-patient 
had continued high fever with sweating and was washed 
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Figure 2. Schematic	floor	plan	of	the	hematology	ward	where	2	case-patients	with	confirmed	avian	influenza	A(H7N9)	and	A(H1N1)
pdm09	virus	co-infection	and	1	non–H7N9-infected	patient	stayed,	Taizhou	Hospital,	Zhejiang	Province,	China,	January	10–15,	2014.	
The	room	was	22.4	m2	(6.4	m	×	3.5	m)	in	floor	area,	with	1	door	(30	cm	×	40	cm)	and	1	window	(105	cm	×	20	cm),	and	0.6	m	of	space	
separated	the	beds	of	the	patients.	H7N9,	avian	influenza	A(H7N9)	virus;	pH1N1,	influenza	A(H1N1)pdm09	virus.
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and had clothes changed by his wife. Neither patient had 
vomiting or diarrhea. The ward floor and surfaces were 
disinfected by using domiphenbromide (1:400 concentra-
tion) twice a day.
Three other patients shared the same ward during this 
period (Figure 2; Table 1). Bed 25 was occupied during 
January 2–17 by patient 3, a 78-year-old man with chronic 
B cell leukemia, and during January 17–22 by patient 5, 
a 61-year-old man with macroglobulinemia. After the in-
dex case-patient was transferred to the ICU, during Janu-
ary 15–23, bed 26 was occupied by patient 4, a 50-year-
old man with acute myeloid leukemia (Figure 1). Patient 
3 was H7N9 virus antibody–negative by HI test 42 days 
and 44 days after his most recent exposures to the second 
case-patient and index case-patient, respectively. Patients 
4 and 5 were negative by rRT-PCR for influenza A viruses 
1 day after their most recent exposures and were negative 
for H7N9 virus antibody by HI test 40 days after their most 
recent exposure to the second case-patient. Because the 
diagnosis of H7N9 virus infection was not suspected dur-
ing their stay in this room, neither the index case-patient 
nor the second case-patient wore a protective mask, and 
the 25 staff or visitors who visited the room did not use any 
personal protective equipment. 
Investigation of Contacts
A total of 68 close contacts of the index case-patient were 
identified, including 2 patients in the hematology ward, 
7 patients in the ICU of the respiratory ward, 51 health-
care workers, 4 household members, and 4 social contacts. 
The median duration of exposure to the index case-patient 
was 3.5 hours (interquartile range [IQR] 2.5–6.5 hours]. 
No close contacts reported taking oseltamivir chemopro-
phylaxis. A total of 64 close contacts of the second case-
patient were identified, including 3 patients in the hema-
tology ward, 6 patients in the ICU, 51 healthcare workers, 
2 household members, and 2 social contacts. None of 
the contacts developed acute respiratory symptoms. The 
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Table 1. Selected	characteristics	of	5	patients	who	shared	the	same	hematology	ward	at	Taizhou	Hospital,	Zhejiang	Province,	China,	
January	2014* 
Characteristic Index	case-patient Case-patient	2 Patient	3 Patient	4 Patient	5 
Demographics	and	medical	history     
 Age,	y 57 71 78 50 61 
 Sex M M M M M 
 Type	of	residence Rural Urban Urban Rural Rural 
 Occupation Farmer Retiree Retiree Farmer Farmer 
 History	of	smoking No Yes No No No 
 History	of	alcohol	use No No No No No 
 Obesity No No No No No 
 Underlying	conditions Chronic	
lymphocytic	
leukemia;	hernia	
operation 
Polycythemia	
vera;	cerebral	
infarction;	
diabetes 
B	cell	lymphocytic	
leukemia;	
hypertension 
Acute	myeloid	
leukemia	(M2a) 
 
Macroglobulinemia;	
gout;	kidney	stone 
 Chronic	drug	use No Yes Yes Yes Yes 
 No.	family	members 5 3 6 4 5 
Exposure	history      
 Birds,	other	animals	at	home Yes No No Yes No 
 Visited	an	LPM Yes No No Yes No 
 Exposure	to	a	febrile	person No Yes Yes Yes Yes 
 Duration	of	exposure,	d	
 (source)	 
— 5	(index	patient) 5	(index	patient);	
11	(patient	2) 
4	(patient	2) 3	(patient	2) 
 Specimen	collection	date	
 (type) 
Jan	19	(throat	swab 
and	serum) 
Jan	21	(throat	
swab	and	serum) 
Jan	26 
(Serum) 
Jan	20 
(throat	swab);	
Jan	26	(serum) 
Jan	20 (throat	
swab);	Jan	26	
(serum) 
 Diagnostic	method Virus	isolation; 
rRT-PCR;	HI 
Virus	isolation; 
rRT-PCR;HI 
HI rRT-PCR;HI rRT-PCR;HI 
 Date of confirmation Jan	19 Jan	21 NA	(negative) NA	(negative) NA	(negative) 
 Laboratory	results H7N9	and 
pH1N1	positive 
H7N9	and 
pH1N1	positive 
Negative Negative Negative 
Clinical	features      
 Exposure	to	onset,	d 1 4 NA NA NA 
 Onset	to	admission,	d 2 6 NA NA NA 
 Onset	to	ICU,	d 7 5 NA NA NA 
 Onset	to	antiviral	drugs,	d 10 6 NA NA NA 
 Onset	to	death,	d 15 10 NA NA NA 
 Days	in	hospital 13 16 23 9 5 
 Date of outcome Jan	23 Jan	24 Jan	17 Jan	23 Jan	22 
 Outcome Died Died Survived Survived Survived 
*H7N9,	avian	influenza	A(H7N9)	virus;	HI,	hemagglutination inhibition;	ICU,	intensive	care	unit;	LPM,	live	poultry	market;	NA,	not	available;	pH1N1,	
influenza	A(H1N1)pdm09	virus;	rRT-PCR,	real-time	reverse	transcription	PCR. 
 
Nosocomial	Cluster	with	A(H7N9)	and	A(H1N1)pdm09
median duration of exposure to at least 1 of the case-pa-
tients was 2 hours (IQR 1–3 hours) (Table 1).
Of the contacts of the index case-patient in the hema-
tology ward, 31 close contacts (2 patients, 21 healthcare 
workers, 4 household members, and 4 social contacts) were 
traced. During the 7-day surveillance period, acute respira-
tory symptoms developed in 1 of 2 patients who shared the 
room in the hematology ward and in 2 of 4 social contacts. 
On January 23, a total of 8 throat swabs were collected from 
2 of patients in the hematology ward, 4 household mem-
bers, and 2 social contacts. Of these, only 1 (case-patient 2) 
was found to be infected with H7N9 virus. For patient 2, a 
total of 28 close contacts (3 patients, 21 healthcare work-
ers, and 4 household members) were traced, and none of 
them had symptoms of disease. Three throat swab samples 
collected from the 3 patients were negative for H7N9 virus.
During January 15–19, a total of 27 close contacts of 
the index case-patient when he was in ICU (20 healthcare 
workers and 7 patients sharing the ICU ward) were traced; 
6 of the patients and 4 of the healthcare workers had throat 
swab samples collected. One of symptomatic patients, a 
71-year-old man who had been in the ICU during Janu-
ary 10–19 and had chronic obstructive pulmonary disease, 
pneumonia, and chronic renal failure, was positive for 
pH1N1 virus by rRT-PCR on throat swab samples collect-
ed on January 20. A total of 26 close contacts of the second 
case-patient (20 healthcare workers and 6 patients sharing 
the ICU ward) were traced. None of them none of them had 
signs or symptoms of disease. Throat swab samples were 
not collected.
Ten healthcare workers had contact with the index case-
patient and 10 with the second case-patient for the periods 
these patients were in the infectious disease ward. All throat 
swab samples collected during January 20–24 from these 
20 contacts were negative for H7N9 and pH1N1 viruses by 
rRT-PCR. Overall, serum samples from 84 contacts who 
consented to have serum collected for testing were negative 
for H7N9 virus antibodies by MN and HI assays.
On January 20, a total of 10 environmental samples 
from the LPM that the index case-patient worked in be-
fore his illness (online Technical Appendix Figure 8) were 
collected; 1 of these was positive for H7N9 and H9N2 vi-
ruses, and another was positive for H7N9 virus. Two throat 
swab samples from workers in this LPM were negative for 
influenza A virus. Furthermore, throughout January 2014, 
environment surveillance results in Linhai District showed 
that 17 (60.71%) of 28 LMPs were positive for H7N9 virus 
(online Technical Appendix Figure 9).
Viral Genetic Sequence Analysis of H7N9  
and pH1N1 Viruses
No virus isolate was obtained from the index case-patient, 
but the partial genome of the virus was obtained by direct 
sequencing from his pharyngeal swab specimens. Full-
length membrane protein and nonstructural gene sequences 
and partial hemagglutinin and neuraminidase sequences 
were obtained. A virus isolate was obtained from the sec-
ond case-patient, and the full virus genome was ascertained. 
Alignment of the membrane protein and neuraminidase se-
quences from the index case-patient with the H7N9 virus 
sequences from the virus isolated from the second case-
patient showed that these 2 sequences shared 99.5% and 
100% nucleic acid sequence identity, respectively. Both 
case-patients had viruses that were oseltamivir-sensitive 
(E120V, H276Y and R294K in neuraminidase protein) 
but amantadine-resistant (S31N in matrix 2 protein). The 
pH1N1 virus neuraminidase gene segment from the index 
case-patient was 100% identical to that from the second 
case-patient.
Serum Cytokine Levels
Serum levels of cytokines and chemokines in the index 
case-patient (10 days after illness onset) and the second 
case-patient (9 days after illness onset) were compared 
with those of 21 other patients infected with H7N9 vi-
rus. Levels of 13 cytokines and chemokines (granulocyte 
colony–stimulating factor, growth-regulated oncogene-a, 
interleukin [IL] 10, IL-12p40, IL-16, IL-18, IL-1 receptor 
antagonist, IL-2 receptor antagonist, IL-3, IL-6, IL-8, leu-
kemia inhibitory factor, monocyte chemoattractant pro-
tein-1, monocyte chemoattractant protein 3, and stromal 
cell–derived factors) from the index case-patient and the 
second case- patient were higher than the upper bound of 
the 95% CIs of the mean levels of other patients infected 
with H7N9 virus (Table 2; online Technical Appendix 
Figure 10). In contrast, levels of interferon-gamma (IFN-
g), IL-2, IL-12, and IL-4, which are correlated with adap-
tive immune responses to influenza viruses, were compa-
rable to those observed in healthy persons but much lower 
than those observed in nonimmunocompromised H7N9 
virus–infected patients (online Technical Appendix Fig-
ure 11). The lack of these cytokines, which are associated 
with the development of T helper (Th) 1, Th2, and Th17 
cells, might have led to an incapable adaptive immune re-
sponse in these 2 case-patients and thereby enhanced the 
pathogenicity of the viruses.
Discussion
Although ≈600 cases caused by H7N9 virus have been re-
ported, 41 clustered cases from 20 disease clusters have 
been reported. The clustered cases accounted for only 5.9% 
of the total cases, so there seems to be evidence of limited 
transmission (10). Our study found epidemiologic differ-
ences between 1 nosocomial cluster caused by co-infection 
with H7N9 and pH1N1 viruses and a previously document-
ed family cluster induced by a single H7N9 virus.
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The index case-patient had been exposed to an LPM 
that was retrospectively proven to be positive for influenza 
H7N9 virus. The second case-patient had no avian expo-
sure but experienced onset of clinical disease within 4 days 
of close contact with the index case-patient. The second 
case-patient was co-infected with H7N9 and pH1N1 virus-
es, as was the index case-patient. Virus genetic sequences 
of H7N9 and pH1N1 viruses from the 2 case-patients were 
identical. These findings strongly suggest nosocomial hu-
man-to-human co-transmission of both influenza viruses in 
2 non–blood-related patients with hematologic disorders. 
The findings also demonstrate a lack of transmission to 
other patients and healthcare workers, reinforcing the con-
tention that H7N9 virus remains poorly transmissible from 
human to human. 
In this particular event, the incubation period was 4 
days, compatible with previous estimates of incubation 
period (11). This incubation period was more plausible 
than the incubation periods of 13 days, 7 days, and 10 
days reported for the Jiangsu (3), Shanghai, and Guang-
dong clusters, respectively (12,13), where infection from 
a common source cannot be ruled out. In other fam-
ily clusters, the index patient’s illness was more severe, 
whereas most of the secondary cases were milder and 
rarely fatal (14,15). The greater disease severity in the 
second case-patient in our study might be attributable to 
the co-infection with influenza pH1N1 virus in combina-
tion with his underlying disease and the delayed initiation 
of antiviral therapy (16).
The exact route of transmission from the index case-
patient to the second case-patient remains unclear. Trans-
mission through respiratory droplets is possible because the 
index case-patient had repeated bouts of coughing, and he 
had several aerosol-generating procedures conducted dur-
ing his hospitalization. Cross-infection through fomites, 
the unwashed hands of healthcare workers or visitors, or 
unsanitary medical equipment might also be possible. Be-
fore the 2 case-patients were confirmed to have H7N9 virus 
infection, no personal protective equipment was used. 
Serologic methods rarely yield an early diagnosis of 
influenza virus. Apart from their retrospective diagnostic 
value, serologic methods are applied in epidemiologic and 
immunologic studies. In our study, we conducted HI and 
MN tests for all contacts of the 2 case-patients under nega-
tive and positive quality control. However, we did not de-
tect any serologic evidence of secondary transmission in 
approximately 84 contacts. The basic reproduction number 
(R0), a measure of transmission potential of H7N9 virus 
compared with pH1N1 virus, was 0.1 versus 1.7, indicating 
that the transmission potential of H7N9 virus was much 
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Table 2. Cytokine	and	chemokine	levels for	controls	compared	with	2	patients	with	confirmed	co-infection	with	avian	influenza	
A(H7N9)	and	A(H1N1)pdm09	viruses,	Taizhou	Hospital,	Zhejiang	Province,	China,	January	2014* 
Cytokine	or	
chemokine 
Healthy	controls,	n	=	6 
 
H7N9-infected	controls.	n	=	21 Index	case-
patient Case-patient	2 Change Mean 95%	CI Mean 95%	CI 
G-CSF 27.6 21.9	to	33.3  47.5 32.1	to	62.9 3421.0 5,759.0  
GROa 260.2 79.6	to	440.8  164.8 89.4 to	240.2 320.8 757.4  
IL-10 0.8 0.4 to	1.2  17.8 12.9 to	22.7 42.2 234.1  
IL-12p40 719.8 59.5 to	1380.1  240.3 28.2 to	508.8 5176.0 585.5  
IL-16 530.0 71.7	to	1131.7  260.8 170.2	to	351.3 627.4 468.51  
IL-18 69.9 31.5	to	108.2  163.7 101.3	to	226.1 530.9 1,501.1  
IL-1Ra 111.8 89.5	to	134.1  218.3 164.3	to	272.2 506.7 1,340.1  
IL-2Ra 79.6 51.2	to	108.1  97.5 49.9 to	145.1 699.9 425.4  
IL-3 101.4 30.9	to	171.8  30.8 0.8 to	62.4 815.3 210.4  
IL-6 4.1 2.8	to	5.4  91.5 50.7 to	132.3 819.6 22,009.0  
IL-8 7.0 2.7 to	11.4  62.2 45.5	to	79.0 1,228.3 2,075.3  
LIF 9.1 0.7	to	17.5  7.9 1.3 to	14.4 34.4 31.2  
MCP-1 7.0 2.9	to	11.0  238.4 91.8	to	384.9 569.7 757.4  
MCP-3 28.5 8.8	to	48.2  8.6 1.4 to	18.7 28.8 39.5  
SDF-1a 83.0 43.4	to	122.6  72.6 37.3	to	107.9 641.8 273.7  
Extaxin 79.7 36.3 to	123.1  108.9 79.1	to	79.1 25.5 36.3  
GM-CSF 0.1 0.04	to	0.1  65.8 44.5	to	87.1 38.8 26.4  
IFN- 66.7 61.3	to	72.1  117.3 91.8	to	142.7 64.3 62.9  
IL-12	p70 8.0 5.3 to	10.7  32.7 25.7	to	39.7 18.0 6.0  
IL-2 3.9 1.9 to	5.8  17.8 13.2 to	22.4 5.3 7.9  
IL-4 2.9 2.2	to	3.5  8.4 6.5	to	10.4 1.2 1.7  
IL-5 1.7 1.1 to	2.2  7.2 4.5	to	10.0 2.1 1.8  
MIG 315.7 189.8	to	441.5  7,860.2 4245.5	to	11,474.9 2,246.4 429.8  
PDGF-bb 532.0 419.8 to	644.3  3,608.5 2,746.0 to	4,471.1 784.5 21.2  
RANTES 613.5 798.5	to	983.5  12,716.5 9,193.1	to	16,239.9 658.5 178.2  
*Levels	are	given	in	pg/mL.	Arrows	indicate	cytokine	and	chemokine	levels	that	were	significantly	higher	()	or	lower	()	in	the	serum	samples	of	the	index	
patient	and	patient	2	compared	with	95%	CIs	of	the	mean	values	of	21	other	patients	infected	with	the	avian	influenza	A(H7N9) virus.	G-CSF,	granulocyte	
colony	stimulating	factor;	GM-CSF,	granulocyte	macrophage colony–stimulating	factor;	GROa,	growth-regulated	oncogene-;	IFN-,	interferon-gamma;	
IL,	interleukin;	MCP,	monocyte	chemoattractant	protein;	MIG,	macrophage-induced	gene	;	PDGF-bb,	platelet-derived	growth	factor	bb;	Ra,	receptor	
antagonist;	RANTES,	regulated	on	activation	normal	T	cell	expressed	and	secreted;	SDF,	stromal	cell–derived	factors. 
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lower than that of pH1N1 virus. Thus, prolonged exposure 
and the immunocompromised status of the 2 case-patients 
might have contributed to the transmission of infection. 
Co-infection of H7N9 and seasonal influenza A(H3N2) 
viruses has been reported in a patient from Jiangsu Prov-
ince, China, but this patient recovered, possibly because of 
his young age (15 years) and early initiation of antiviral 
treatment; evidence of secondary transmission was not ac-
tively sought (17).
Patients with hematologic malignancy, such as chronic 
lymphocytic leukemia and polycythemia vera, have mul-
tiple immune defects (18–21), including defects in T-cell 
function and natural killer cell dysfunction, decreased an-
tibody responses, and abnormal cytokine production (21). 
Patients with such disorders are thus more prone to new 
infections and prolonged virus shedding (18,20,22–28). 
For example, a patient with chronic lymphocytic leukemia 
who was not in an ICU was infected with pH1N1 virus and 
continued to shed virus for 59 days; antiviral resistance 
developed, consistent with the patient’s immunocompro-
mised condition (28). In our study, the index case-patient 
was confirmed as H7N9 virus–positive on day 11 after 
illness onset, which suggests prolonged viral shedding in 
older, immunocompromised patients. However, the conse-
quences of H7N9 patients with hematologic malignancies 
are poorly understood in terms of clinical outcomes and 
transmission potential.
Innate immune dysregulation might contribute to 
the pathogenesis of severe avian influenza (29). In our 
study, the 2 H7N9 virus–infected case-patients who died 
had chronic lymphocytic leukemia and polycythemia 
vera, respectively. Chronic lymphocytic leukemia is as-
sociated with dysfunction of innate and adaptive immu-
nity (21,30,31). Cytokines, such as IL-8, associated with 
acute respiratory distress syndrome (32), and IL-6, associ-
ated with severe cytokine-release syndrome, can occur in 
chronic lymphocytic leukemia patients after treatment with 
rituximab, an anti-CD20 monoclonal antibody (33). The 
underlying disease (polycythemia vera) in the second case-
patient is associated with Janus kinase 2 mutation V617F, 
which leads to constitutive tyrosine phosphorylation activ-
ity that promotes cytokine hypersensitivity, including IL-3 
and stem cell factor (34,35). The abnormal signaling path-
way in cells of patients with polycythemia vera can also 
contribute to growth of fibroblasts and microvascular endo-
thelial cells and induce the production of profibrogenic and 
angiogenic cytokines (36).
Hypercytokinemia has been reported in the periph-
eral blood of H7N9 virus–infected patients with substan-
tially elevated levels of cytokines and chemokines (e.g., 
IL-1b, IL-6, IL-8, IL-10, IL-12, IL-17, monokine induced 
by IFN-g, macrophage inflammatory proteins 1a and 
1b, monocyte chemotactic protein 1, interferon-induced 
protein of 10 kDa, and regulated on activation normal T 
cell expressed and secreted [RANTES]) (5,29,37,38). De-
spite underlying immune defects in the context of steroid 
therapy, the 2 H7N9 virus–infected case-patients in our 
study mounted strong proinflammatory cytokine respons-
es (e.g., production of IL6, IL8, and monocyte chemotac-
tic protein 1), even stronger than those observed in other 
nonimmunocompromised patients with H7N9 infection. 
On the other hand, levels of cytokines known to correlate 
with immune protection against influenza viruses, such as 
IL-2, IL-4 and IFN-g, which contribute to development 
of Th1, Th2, and Th17 cells, were observed to be much 
lower in the 2 case-patients reported here compared with 
other H7N9 virus–infected patients. Thus, disorders of in-
nate immune and adaptive immune responses in these 2 
case-patients might have contributed to the disease sever-
ity and fatal outcomes.
In summary, our findings strongly suggests nosocomi-
al human-to-human co-transmission of H7N9 and pH1N1 
viruses between 2 immunocompromised case-patients with 
hematologic diseases, with no evidence of transmission to 
others. The deaths of these 2 case-patients might have been 
attributable to co-infection with pH1N1 virus, delayed ini-
tiation of antiviral therapy, and the patients’ immunocom-
promised status. These findings suggest the need for aware-
ness and early testing for influenza in hematology units and 
for liberal use of early antiviral treatment if patients exhibit 
ILI symptoms. Implementing rigorous infection control 
practices might minimize cross-transmission. Avoiding the 
use of corticosteroids in patients with infection also needs 
to be emphasized.
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